Overview

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

Status:
Completed
Trial end date:
2019-08-19
Target enrollment:
Participant gender:
Summary
An open label extension to the RHB-104-01 Study.
Phase:
Phase 3
Details
Lead Sponsor:
RedHill Biopharma Limited
Treatments:
Clarithromycin
Clofazimine
Rifabutin